Depletion of complement system immunity in patients with myocardial infarction

Area of Science:

• Cardiovascular Medicine
• Immunology
• Molecular Biology

Background:

• The complement system plays a critical role in innate immunity.
• Dysregulation of the complement system has been implicated in various cardiovascular diseases.
• Understanding complement system involvement in myocardial infarction (MI) is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate differences in complement system gene expression and serum levels in patients with acute myocardial infarction (AMI), stable angina (SA), and healthy controls.
• To elucidate the role of complement activation and potential dysfunction in the pathogenesis of AMI.

Main Methods:

• Whole human genome microarray analysis was used to assess complement gene expression in 60 subjects (20 per group).
• Serum levels of complement components CH50, C3, and C4 were measured in all 300 participants (100 AMI, 100 SA, 100 controls).
• Statistical analyses were performed to compare gene expression and serum levels between groups.

Main Results:

• Patients with AMI showed significantly higher expression of genes encoding complement components (e.g., C1q, C5a), receptors (e.g., CR1, C5aR), and regulators (e.g., CD46, CD55) compared to SA and control groups.
• Conversely, mRNA levels of certain complement components (C1s, C7, C8β, C9) were lowest in the AMI group.
• Serum levels of CH50, C3, and C4 were elevated in both AMI and SA groups compared to controls, indicating complement system activation.
• No significant differences in complement gene expression were observed between the SA and control groups.

Conclusions:

• The complement system is activated in patients with AMI and SA.
• Differential gene expression patterns in AMI suggest a potential dysfunction of the C5b-9 complex.
• Complement system dysregulation and immune depression may contribute to the pathogenesis of myocardial infarction.